Critical research concepts in tuberculosis vaccine development

Clinical Microbiology and Infection

Volumn 20, Issue S5, 2014, Pages 59-65

  Delogu, G ^a   Manganelli, R ^b   Brennan, M J ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c AERAS   (United States)

Author keywords

Bacillus Calmette Gu rin; Disease transmission; Mycobacterium tuberculosis; Tuberculosis; Vaccines

Indexed keywords

BCG VACCINE; BACTERIAL ANTIGEN; MYCOBACTERIUM TUBERCULOSIS ANTIGENS;

ANTIBODY RESPONSE; ANTIBODY TITER; BCG VACCINATION; CELLULAR IMMUNITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; CYTOLOGY; IMMUNOLOGY; MYCOBACTERIUM BOVIS; VACCINATION;

MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

ANTIGENS, BACTERIAL; BCG VACCINE; HUMANS; MYCOBACTERIUM BOVIS; T-LYMPHOCYTES; TUBERCULOSIS; VACCINATION;

EID: 84897487544     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12460     Document Type: Review

References (75)

1. World Health Organization. Global TB report 2013. 2013.
2. Cegielski JP. Extensively drug-resistant TB: "there must be some kind of way out of here". Clin Infect Dis 2010; 50 (Suppl 3): S195-S200.
3. Rowland K. Totally drug-resistant TB emerges in India. Nature 2012; 1.9797.
4. Brennan MJ, Thole J. TB vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S6-S13.
5. Brosch R, Gordon SV, Garnier T et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007; 104: 5596-5601.
6. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel TB vaccine. Nat Rev Microbiol 2005; 3: 656-662.
7. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-1345.
8. Colditz GA, Berkey CS, Mosteller F et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of TB: meta-analyses of the published literature. Pediatrics 1995; 96 (1 Pt 1): 29-35.
9. Kaufmann SH. Future vaccination strategies against TB: thinking outside the box. Immunity 2010; 33: 567-577.
10. Kaufmann SH. Fact and fiction in TB vaccine research: 10 years later. Lancet Infect Dis 2011; 11: 633-640.
11. Brennan MJ, Stone MR, Evans T. A rational vaccine pipeline for TB. Int J Tuberc Lung Dis 2012; 16: 1566-1573.
12. Ottenhoff TH, Kaufmann SH. Vaccines against TB: where are we and where do we need to go? PLoS Pathog 2012; 8: e1002607.
13. Evans TG, Brennan MJ, Barker L, Thole J. Preventive vaccines for TB. Vaccine 2013; 31 (suppl 2): B223-B226.
14. Arbues A, Aguilo JI, Gonzalo-Asensio J et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013; 31: 4867-4873.
15. Hernandez PR, Aguilar LD, Smith I, Manganelli R. Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary TB. Infect Immun 2010; 78: 3168-3176.
16. Hinchey J, Jeon BY, Alley H et al. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for TB. PLoS One 2011; 6: e15857.
17. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galič S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against TB than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000; 97: 13853-13858.
18. Pym AS, Brodin P, Majlessi L et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against TB. Nat Med 2003; 9: 533-539.
19. + induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011; 204: 1573-1584.
20. Sun R, Skeiky YA, Izzo A et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009; 27: 4412-4423.
21. Sali M, Di Sante G, Cascioferro A et al. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun 2010; 78: 5202-5213.
22. Sweeney KA, Dao DN, Goldberg MF et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011; 17: 1261-1268.
23. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new TB vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-1028.
24. Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary TB. PLoS One 2009; 4: e5856.
25. Hoft DF, Blazevic A, Stanley J et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012; 30: 2098-2108.
26. van Dissel JT, Soonawala D, Joosten SA et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or TB infection. Vaccine 2011; 29: 2100-2109.
27. Lin PL, Dietrich J, Tan E et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active TB and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012; 122: 303-314.
28. Aagaard C, Hoang TT, Izzo A et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 2009; 4: e5930.
29. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate TB vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010; 17: 1763-1771.
30. Bertholet S, Ireton GC, Ordway DJ et al. A defined TB vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2: 53ra74.
31. Parra M, Pickett T, Delogu G et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of TB. Infect Immun 2004; 72: 6799-6805.
32. von Reyn CF, Mtei L, Arbeit RD et al. Prevention of TB in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24: 675-685.
33. Vilaplana C, Gil O, Caceres N, Pinto S, Diaz J, Cardona PJ. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One 2011; 6: e20404.
34. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. TB and HIV co-infection. PLoS Pathog 2012; 8: e1002464.
35. Wallis RS. Tumour necrosis factor antagonists: structure, function, and TB risks. Lancet Infect Dis 2008; 8: 601-611.
36. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
37. Flynn JL. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 2006; 8: 1179-1188.
38. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in TB. Annu Rev Immunol 2013; 31: 475-527.
39. Dannenberg AM Jr. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of TB. Immunobiology 1994; 191: 461-473.
40. Orme IM, Cooper AM. Cytokine/chemokine cascades in immunity to TB. Immunol Today 1999; 20: 307-312.
41. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171: 1602-1609.
42. Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of TB. Tuberculosis (Edinb) 2005; 85: 29-38.
43. Verreck FA, Vervenne RA, Kondova I et al. MVA.85A boosting of BCG and an attenuated, phoP deficient Mycobacterium tuberculosis vaccine both show protective efficacy against TB in rhesus macaques. PLoS One 2009; 4: e5264.
44. + T cells. Eur J Immunol 2010; 40: 279-290.
45. Scriba TJ, Tameris M, Mansoor N et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 2011; 203: 1832-1843.
46. Dye C, Fine PE. A major event for new TB vaccines. Lancet 2013; 381: 972-974.
47. Comas I, Chakravartti J, Small PM et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42: 498-503.
48. + Th1 subset. PLoS Pathog 2013; 9: e1003130.
49. Gagneux S. Host-pathogen coevolution in human TB. Philos Trans R Soc Lond B Biol Sci 2012; 367: 850-859.
50. Delogu G, Li A, Repique C, Collins F, Morris SL. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary TB. Infect Immun 2002; 70: 292-302.
51. Younga D, Verreck FA. Creativity in TB research and discovery. Tuberculosis (Edinb) 2012; 92 (suppl 1): S14-S16.
52. Barry CE III, Boshoff HI, Dartois V et al. The spectrum of latent TB: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-855.
53. Elkington PT. TB: time for a new perspective? J Infect 2013; 66: 299-302.
54. Kruh NA, Troudt J, Izzo A, Prenni J, Dobos KM. Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo. PLoS One 2010; 5: e13938.
55. Iantomasi R, Sali M, Cascioferro A et al. PE_PGRS30 is required for the full virulence of Mycobacterium tuberculosis. Cell Microbiol 2012; 14: 356-367.
56. Brennan MJ, Delogu G. The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol 2002; 10: 246-249.
57. Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012; 36: 514-532.
58. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent TB: can disease be predicted? Trends Mol Med 2007; 13: 175-182.
59. Diel R, Goletti D, Ferrara G et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
60. Pai M, Joshi R, Dogra S et al. T-cell assay conversions and reversions among household contacts of TB patients in rural India. Int J Tuberc Lung Dis 2009; 13: 84-92.
61. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174: 831-839.
62. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995; 171: 1387-1398.
63. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998; 11: 514-532.
64. Achkar JM, Casadevall A. Antibody-mediated immunity against TB: implications for vaccine development. Cell Host Microbe 2013; 13: 250-262.
65. Achkar JM, Jenny-Avital E, Yu X et al. Antibodies against immunodominant antigens of Mycobacterium tuberculosis in subjects with suspected TB in the United States compared by HIV status. Clin Vaccine Immunol 2010; 17: 384-392.
66. Glatman-Freedman A, Mednick AJ, Lendvai N, Casadevall A. Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M. Infect Immun 2000; 68: 335-341.
67. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003; 1: 17-24.
68. Armstrong JA, Hart PD. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med 1975; 142: 1-16.
69. 2+ signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J Exp Med 2000; 191: 287-302.
70. Pethe K, Alonso S, Biet F et al. The heparin-binding haemagglutinin of Mycobacterium tuberculosis is required for extrapulmonary dissemination. Nature 2001; 412: 190-194.
71. Teitelbaum R, Glatman-Freedman A, Chen B et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 1998; 95: 15688-15693.
72. Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 2004; 138: 30-38.
73. Fenton MJ, Riley LW, Schlesinger LS. Receptor-mediated recognition of Mycobacterium tuberculosis by host cells. In: Cole ST, ed., TB and the tubercle bacillus. Washington, DC: ASM Press, 2008; 405-426.
74. Maione D, Margarit I, Rinaudo CD et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005; 309: 148-150.
75. Shahin RD, Cowell JL. Mouse respiratory infection models for pertussis. Methods Enzymol 1994; 235: 47-58.